Autotelic Bio
About Autotelic Bio
Categories
-
KR
-
2021On CPHI since
-
25 - 49Employees
Company types
Products from Autotelic Bio (3)
-
Product ATB-330
[ALK5 inhibitor / Small Molecule / Develop for IPF and Fibrosis) – Complete to derivate the lead compound
1. Confirm the highest ALK5 selectivity with superior efficacy and PK profile through in-vivo tests compared to competitors (small molecule new drugs)
... -
Product ATB-101
[ARB+SGLT-2i Fixed Dose Combination] – In process of Phase 3 clinical trial on approx. 250 patients
1. The first Fixed Dose Combination treating hypertension and type 2 diabetes by a tablet in the world
2. Expect the synergistic effect in the treatment of hypertension though mi... -
Product ATB-301
[TGF-β2 Targeting ASO (TASO) + IL-2 Combination therapy] - Phase Ib
1. Confirm the potential of TGF-β2 as a biomarker in human blood and tumor tissues from the efficacy result of Phase Ib clinical trial on cancer patients
2. Confirm the suppression of IL-2’s side effect in combinati...
Autotelic Bio Resources (1)
-
Brochure Autotelic Bio's Brochure
We have several pipelines under deveopment
Oncology
ATB-301
ATB-320
Fixed Dose Combination
ATB-101
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance